Autor: "Chang PY" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.
Autorzy:: Wu YY; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan, Republic of China.
Huang TC; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Tsai TN; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan, Republic of China.; Division of Cardiology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Chen JH; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan, Republic of China.
Dai MS; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Chang PY; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Ho CL; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Ye RH; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Chung TR; National Institute of Cancer Research, Miaoli County, Taiwan, Republic of China.
Chen YC; Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, Taipei City, Taiwan, Republic of China.
Chao TY; Graduate Institute of Life Sciences, National Defense Medical Center, Taipei City, Taiwan, Republic of China.; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan, Republic of China.; Division of Hematology and Oncology, Department of Medicine, Taipei Medical University, Shuang-Ho Hospital, New Taipei City, Taiwan, Republic of China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Mar 08; Vol. 11 (3), pp. e0151112. Date of Electronic Publication: 2016 Mar 08 (Print Publication: 2016).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*metabolism
Receptor, ErbB-2/*metabolism
Trastuzumab/*administration & dosage
Trastuzumab/*adverse effects
Adult ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Cardiotoxicity ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/physiopathology ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Autorzy:: Ko JC; Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Taiwan.; Department of Nursing, Yuanpei University, Hsinchu, Taiwan.
Syu JJ; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.
Chen JC; Department of Food Science, National Chiayi University, Chiayi, Taiwan.
Wang TJ; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.
Chang PY; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.
Chen CY; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.
Jian YT; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.
Jian YJ; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.
Lin YW; Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan.; Pokaż więcej
Źródło:: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2015 Dec; Vol. 117 (6), pp. 383-91. Date of Electronic Publication: 2015 Jun 30.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Carcinoma, Non-Small-Cell Lung/*drug therapy
DNA-Binding Proteins/*metabolism
Drug Resistance, Neoplasm/*drug effects
Etoposide/*pharmacology
Lung Neoplasms/*drug therapy
Mitogen-Activated Protein Kinase 1/*metabolism
Mitogen-Activated Protein Kinase 3/*metabolism
Proto-Oncogene Proteins c-akt/*metabolism
Stilbenes/*pharmacology
Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; DNA-Binding Proteins/genetics ; Dose-Response Relationship, Drug ; Down-Regulation ; Gene Expression Regulation, Enzymologic ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; MAP Kinase Kinase 1/genetics ; MAP Kinase Kinase 1/metabolism ; Phosphorylation ; Proto-Oncogene Proteins c-akt/genetics ; RNA Interference ; Resveratrol ; Signal Transduction/drug effects ; Time Factors ; Transfection ; X-ray Repair Cross Complementing Protein 1

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Autorzy:: Lu CS; Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Chang PY; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Chen YG; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Chen JH; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Wu YY; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ho CL; Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Sep 18; Vol. 10 (9), pp. e0138632. Date of Electronic Publication: 2015 Sep 18 (Print Publication: 2015).
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colonic Neoplasms/*drug therapy
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Chemotherapy, Adjuvant ; Colonic Neoplasms/mortality ; Colonic Neoplasms/pathology ; Colonic Neoplasms/surgery ; Combined Modality Therapy ; Female ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/therapeutic use ; Oxaliplatin ; Precision Medicine ; Prognosis ; Retrospective Studies ; Tegafur/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
Autorzy:: Lu CS; Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center , Taipei , Taiwan.
Chen JH
Huang TC
Wu YY
Chang PY
Dai MS
Chen YC
Ho CL; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2015 Jul; Vol. 56 (7), pp. 2047-55. Date of Electronic Publication: 2015 Jan 14.
Typ publikacji:: Journal Article
MeSH Terms:: Organ Specificity*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Lymphoma, Large B-Cell, Diffuse/*pathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Neoplasm Staging ; Prednisone/administration & dosage ; Prognosis ; Retrospective Studies ; Rituximab/administration & dosage ; Survival Rate ; Vincristine/administration & dosage ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Chang PY"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język